Channing Capital Management LLC Sells 21,887 Shares of Charles River Laboratories Intl. Inc (CRL)

Channing Capital Management LLC decreased its stake in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 3.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 666,615 shares of the medical research company’s stock after selling 21,887 shares during the period. Charles River Laboratories Intl. accounts for about 3.2% of Channing Capital Management LLC’s portfolio, making the stock its largest holding. Channing Capital Management LLC owned 1.39% of Charles River Laboratories Intl. worth $89,686,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in CRL. FMR LLC boosted its holdings in Charles River Laboratories Intl. by 51.9% in the 3rd quarter. FMR LLC now owns 1,869,469 shares of the medical research company’s stock valued at $251,518,000 after purchasing an additional 638,644 shares during the period. First Trust Advisors LP boosted its holdings in Charles River Laboratories Intl. by 56.7% in the 3rd quarter. First Trust Advisors LP now owns 858,962 shares of the medical research company’s stock valued at $115,565,000 after purchasing an additional 310,975 shares during the period. BlackRock Inc. boosted its holdings in Charles River Laboratories Intl. by 7.0% in the 2nd quarter. BlackRock Inc. now owns 4,446,965 shares of the medical research company’s stock valued at $499,216,000 after purchasing an additional 292,685 shares during the period. Bank of Montreal Can boosted its holdings in Charles River Laboratories Intl. by 1,910.1% in the 3rd quarter. Bank of Montreal Can now owns 221,355 shares of the medical research company’s stock valued at $29,781,000 after purchasing an additional 210,343 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in Charles River Laboratories Intl. by 51.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 396,451 shares of the medical research company’s stock valued at $53,339,000 after purchasing an additional 134,594 shares during the period. 96.20% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE CRL opened at $134.85 on Monday. The company has a quick ratio of 1.32, a current ratio of 1.55 and a debt-to-equity ratio of 1.32. Charles River Laboratories Intl. Inc has a 52-week low of $96.70 and a 52-week high of $138.89. The company has a market capitalization of $6.49 billion, a price-to-earnings ratio of 22.74, a price-to-earnings-growth ratio of 1.90 and a beta of 0.74.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 7th. The medical research company reported $1.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.38 by $0.15. Charles River Laboratories Intl. had a net margin of 6.39% and a return on equity of 25.08%. The firm had revenue of $585.30 million during the quarter, compared to analysts’ expectations of $567.58 million. During the same period in the prior year, the company posted $1.30 EPS. The company’s revenue was up 26.1% on a year-over-year basis. As a group, research analysts expect that Charles River Laboratories Intl. Inc will post 5.92 earnings per share for the current year.

In other news, insider David Ross Smith sold 1,866 shares of the company’s stock in a transaction on Monday, November 12th. The shares were sold at an average price of $134.49, for a total value of $250,958.34. Following the sale, the insider now directly owns 12,341 shares of the company’s stock, valued at approximately $1,659,741.09. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David P. Johst sold 23,356 shares of the company’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $136.00, for a total transaction of $3,176,416.00. Following the completion of the sale, the insider now directly owns 219,849 shares in the company, valued at $29,899,464. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,288 shares of company stock worth $3,930,176. Insiders own 2.10% of the company’s stock.

Several brokerages have recently commented on CRL. Morgan Stanley boosted their target price on shares of Charles River Laboratories Intl. from $102.00 to $112.00 and gave the company a “hold” rating in a research report on Tuesday, September 11th. Barclays boosted their target price on shares of Charles River Laboratories Intl. from $110.00 to $120.00 and gave the company an “equal weight” rating in a research report on Thursday, August 9th. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Credit Suisse Group boosted their target price on shares of Charles River Laboratories Intl. from $121.00 to $128.00 and gave the company a “neutral” rating in a research report on Tuesday, September 25th. Finally, Raymond James boosted their target price on shares of Charles River Laboratories Intl. from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 8th. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $130.56.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/12/03/channing-capital-management-llc-sells-21887-shares-of-charles-river-laboratories-intl-inc-crl.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Asset Allocation

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply